Dr. Hahn on Patients With Prostate Cancer Whom Neither Docetaxel or Abiraterone is an Option
September 11th 2018Andy Hahn, MD, a resident at the University of Utah School of Medicine, discusses therapy for patients with prostate cancer whom neither docetaxel or abiraterone acetate (Zytiga) is an option.
Read More